Get the Stockscreener App
8.98
0.90%
+0.08
After Hours:
8.98
Tscan Therapeutics Inc stock is currently priced at $8.98, with a 24-hour trading volume of 177.73K.
It has seen a +0.90% increased in the last 24 hours and a +33.04% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $8.91 pivot point. If it approaches the $9.08 resistance level, significant changes may occur.
Previous Close:
$8.90
Open:
$8.85
24h Volume:
177.73K
Market Cap:
$474.71M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-3.1073
EPS:
-2.89
Net Cash Flow:
$-64.50M
1W Performance:
+16.17%
1M Performance:
+33.04%
6M Performance:
+67.85%
1Y Performance:
+151.54%
1D Range:
$8.735
$9.01
52W Range:
$1.93
$9.36
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857 399 9500
Address
830 Winter Street, Waltham
Tscan Therapeutics Inc Stock (TCRX) Latest News
Lifesci Capital Research Analysts Decrease Earnings Estimates for TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Defense World
Analysts Issue Forecasts for TScan Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:TCRX) - MarketBeat
MarketBeat
BTIG Research Begins Coverage on TScan Therapeutics (NASDAQ:TCRX) - MarketBeat
MarketBeat
HC Wainwright Analysts Lower Earnings Estimates for TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Defense World
Long Term Trading Analysis for (TCRX) - Stock Traders Daily
Stock Traders Daily
TScan Therapeutics' (TCRX) Buy Rating Reiterated at HC Wainwright - Defense World
Defense World
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Tscan Therapeutics Inc (TCRX) Revenue 2024
TCRX reported a revenue (TTM) of $21.05 million for the quarter ending December 31, 2023, a +55.52% rise year-over-year.
Tscan Therapeutics Inc (TCRX) Net Income 2024
TCRX net income (TTM) was -$89.22 million for the quarter ending December 31, 2023, a -34.73% decrease year-over-year.
Tscan Therapeutics Inc (TCRX) Cash Flow 2024
TCRX recorded a free cash flow (TTM) of -$64.50 million for the quarter ending December 31, 2023, a +8.80% increase year-over-year.
Tscan Therapeutics Inc (TCRX) Earnings per Share 2024
TCRX earnings per share (TTM) was -$1.79 for the quarter ending December 31, 2023, a +34.91% growth year-over-year.
Tscan Therapeutics Inc Stock (TCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BARBERICH TIMOTHY J | Director |
Dec 18 '23 |
Buy |
4.89 |
28,830 |
140,881 |
66,710 |
| Klencke Barbara | Director |
Dec 14 '23 |
Buy |
5.08 |
5,000 |
25,400 |
30,000 |
| BARBERICH TIMOTHY J | Director |
Jun 02 '23 |
Buy |
2.63 |
37,880 |
99,564 |
37,880 |
| Lynx1 Capital Management LP | 10% Owner |
May 31 '23 |
Sale |
2.52 |
25,400 |
63,952 |
5,224,600 |
About Tscan Therapeutics Inc
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
0.77%
1.20%
Cap:
|
Volume (24h):